You are here: Industry Insights > ,

News List

The Curtain Has Risen on the Competition for the First Generic Drug, so What Other Innovative Drugs in the Rare Disease Field Can We Look Forward to? Xiaobin
January 23, 2025
The CDE website shows Qilu Pharmaceutical applied for the marketing of nusinersen generic. Once controversial for high price, it treats SMA. Now many firms are involved, and SMA treatment progresses.
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
A Record High! A Review of Blockbuster New Drugs in China in 2024, with the Number of Innovative Drugs Reaching New Heights! Sophia
January 23, 2025
In 2024, China's pharmaceutical field thrived. NMPA approved 220 new drugs, including 46 Class 1 innovative ones with anti-tumor drugs being the most. New anti-tumor drugs offered hope, and the R&D environment will keep improving.
Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
Established Pharmaceutical Company Makes a High-profile Entrance with "Unlimited" R&D Investment, Signaling an Imminent Explosion in This Emerging Field xiaobin
December 20, 2024
Recently, Northeast Pharm announced its plan to acquire a 70% stock equity in Dingcheng Taiyuan for a total cash consideration of approximately RMB 187 million, thereby obtaining controlling stake in the company.
Buyers and Sellers in the Weight Loss M&A Market：Without Buying and Selling, There's No Reshuffle Krebs Qin
December 20, 2024
The development of weight-loss drugs is currently one of the hottest topics in the pharmaceutical industry.
Universal CAR-T, Transaction +1 xiaobin
December 20, 2024
CAR-T therapy (chimeric antigen receptor t-cell immunotherapy) has been a favorite of the innovative drug market in recent years.
20 Years of Growth and Innovation in China, Fette Compacting Launches F30p Tablet Press PharmaSources
December 13, 2024
Interview Dr. Andreas Risch——Managing Director of Fette Compacting (China) Co., Ltd.
The Multifaceted Benefits of Guaraná: Energy, Cognition, and Beyond David Orchard-Webb
December 04, 2024
Guaraná (Paullinia cupana) is a climbing plant endemic to the Amazon region, namely Brazil. This article looks at Guaraná's medicinal potential, traditional usage, and rising significance in modern health applications.
Innovative Strategies to Accelerate Drug R&D, and Regulatory Approvals Saher Haider
October 15, 2024
Global health crises, with the COVID-19 pandemic being the most predominant one, revealed the importance and the stark inefficiencies of traditional drug development pathways.